WAVEMAN · COMPANY

AUTL · Autolus Therapeutics Plc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

AUTL

Name: Autolus Therapeutics plc (AUTL) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Autolus Therapeutics plc

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001730463

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$15.7K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+644.9%

XBRL, annual

NET MARGIN

-381.4%

CONVERSIONS · 180D

codes C/M, not in net · $47.0K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$15.7K over 180 days

-$15.7K over 90 days

more than 62% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

37 funds added or opened last quarter

below 61% of Pharma & Biotech

REVENUE

+644.9% year over year

more than 95% of Pharma & Biotech

MARGIN

-381.4% net margin

below 80% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

5.2% of shares outstanding short · 16.6 days to cover · settled 2026-07-31

more than 56% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

37 funds added or opened positions in the latest 13F quarter, of 84 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +58.9%

+58.9%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $15.7K sold by insiders over 180 days, 37 funds added last quarter, $15.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Autolus Therapeutics plc insiders sold a net $15.7K of stock across 1 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Piccina Cintia

U.S. CCO & Country Gen Manager

SELL

2026-09-02

6,713.0

$15.7K

1 TRANSACTION ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

MAK CAPITAL ONE LLC

33,621,487.0 sh

$53.8M

Blackstone Inc.

20,485,611.0 sh

$32.8M

Syncona Portfolio Ltd

16,640,720.0 sh

$26.6M

ARMISTICE CAPITAL, LLC

15,000,000.0 sh

$24.0M

Tetragon Partners GP Ltd

9,500,000.0 sh

$15.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Piccina Cintia

FILED 2026-09-02

$15.7K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco NASDAQ Future Gen 200 ETF

$80.4K POSITION · AS OF 2026-02-28

0.6%

Invesco Nasdaq Biotechnology ETF

$19.2K POSITION · AS OF 2026-02-28

0.0%

iShares Biotechnology ETF

$1.8M POSITION · AS OF 2026-03-31

0.0%

BlackRock Health Sciences Opportunities Portfolio

$1.2M POSITION · AS OF 2026-02-27

0.0%

ProShares Ultra Nasdaq Biotechnology

$15.8K POSITION · AS OF 2026-02-28

0.0%

State Street(R) SPDR(R) S&P(R) International Small Cap ETF

$115.3K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2023-09
REVENUE	$75.4M	$10.1M	$1.7M	—
OPERATING INCOME	$-270.5M	$-241.4M	$-179.7M	—
NET INCOME	$-287.5M	$-220.7M	$-208.4M	—
EPS (DILUTED)	-1.08	-0.86	-1.20	—
OPERATING CASH FLOW	$-283.6M	$-206.3M	$-145.6M	—
CASH	$104.1M	$227.4M	$239.6M	$256.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE